Skip to main content
SpringerLink
Log in

Albumin cost effective in decompensated cirrhosis

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2017 euros

Reference

  • Runken MC, et al. The cost-effectiveness of albumin in the treatment of decompensated cirrhosis in Germany, Italy, and Spain. Health Economics Review 9: No. 22, 5 Jul 2019. Available from: URL: https://doi.org/10.1186/s13561-019-0237-7

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Albumin cost effective in decompensated cirrhosis. PharmacoEcon Outcomes News 833, 7 (2019). https://doi.org/10.1007/s40274-019-6071-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-6071-7

Search

Navigation